Chemo-immunotherapy without anthracycline for early triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at how well a chemotherapy and immunotherapy combination works for early-stage triple-negative breast cancer when no anthracycline drugs are used. It could help avoid heart-related side effects from anthracyclines while still treating the cancer effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have early-stage triple-negative breast cancer
- You received chemotherapy with immunotherapy before surgery, and no anthracycline drugs were used
- You have had surgery to remove the tumor, and a pathology report is available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This study compares two types of pre-surgery treatment (chemotherapy and immunotherapy) for triple-negative breast cancer to see which works better. You would be eligible if you've already completed this treatment and had surgery.
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.